BrokenTruth.TV
28 Months Later: FDA Still Hasn't Revealed Rick Bright and Janet Woodcock's Communications
Why It Matters
Understanding how regulatory decisions were made during the pandemic is crucial for evaluating public health outcomes and restoring trust in institutions like the FDA. The episode highlights the potential consequences of politicized drug approvals, reminding listeners why transparency and evidence‑based policy are essential for future health crises.
Key Takeaways
- •FDA delayed hydroxychloroquine EUA despite Bright's recommendation.
- •Woodcock previously approved opioids, raising conflict concerns.
- •FOIA request for Bright-Woodcock emails faces 24‑month backlog.
- •Whistleblower claims political pressure suppressed early COVID‑treatment options.
- •Critics label Woodcock’s FDA leadership as dangerous appointment.
Pulse Analysis
The episode centers on a 2020 clash between virologist Rick Bright and FDA Commissioner Janet Woodcock over hydroxychloroquine. Bright urged the agency to issue an Emergency Use Authorization (EUA) for early COVID‑19 treatment, while Woodcock pushed for a more restrictive expanded‑access IND protocol. The hosts argue that this internal disagreement, amplified by political pressure from the White House, delayed a drug that had been used safely for malaria for decades, potentially costing lives.
Beyond the hydroxychloroquine dispute, the discussion highlights Woodcock’s broader regulatory track record. She oversaw approvals for powerful opioids such as OxyContin and fentanyl, drugs linked to millions of American deaths, and sat on the editorial board that published the discredited Surgisphere study. Listeners learn that a Freedom of Information Act request for communications between Bright and Woodcock is stalled in a queue of over 1,100 requests, projecting a 24‑month wait before any documents surface.
For business leaders, the conversation underscores the strategic risk of regulatory capture and delayed transparency. When the FDA’s top officials have ties to pharmaceutical profit streams, policy decisions can sway market dynamics, affect drug availability, and erode public trust. Understanding these dynamics helps executives anticipate regulatory shifts, manage compliance risk, and evaluate the credibility of public‑health guidance during crises.
Episode Description
The 'dangerous' narrative about cheap, affordable HCQ came down to communications between BARDA's Rick Bright and the FDA's Janet Woodcock. Why can't the FDA release these records?
Comments
Want to join the conversation?
Loading comments...